25 research outputs found
FMECA and FTA analysis applied to the manufacturing process of pulsating heat pipes
Pulsating heat pipes (PHPs) offer significant advantages for the thermal control of electronic components due to their simple manufacturing and high heat transfer rates. The reliability of PHPs has traditionally been assessed through long-life testing, but detailed reliability analyses from an equipment perspective are limited. The study of PHP reliability is essential due to its application and operational conditions. For instance, in aerospace applications these devices operate under severe conditions, and maintenance or replacement is impossible during operation, making them critical components in system functionality. The reliability analysis of PHPs focuses on the manufacturing process, considering future operating conditions. Although preliminary PHP testing will be conducted on Earth, laboratory conditions are less stringent due to the difficulty of replicating launch acceleration and space conditions for long-term testing under microgravity. This study presents an FMECA (Failure Modes, Effects, and Criticality Analysis) of the pulsating heat pipe manufacturing process, breaking down the production of each component. The results indicate that the most critical point is concentrated in the assembly of these components, leading to a higher incidence of welding failures. It recommends further work to improve welding and analyze mechanical stresses within the heat pipe
Evaluation of a cocoa dryer prototype using LabVIEW software and Arduino hardware
In a country like Colombia, food drying plays an important role in the extension of technology so that farmers improve the quality of their productivity. The objective of this work is to develop a system for acquiring thermodynamic variables, to establish the energy efficiency of a product drying oven, specifically for cocoa beans using Arduino hardware and LabView software. This research begins by establishing the variables to be measured and recorded by the DHT11 sensors, such as temperature and humidity. These sensors are connected to an Arduino Uno board that has an Atmel microcontroller, which captures the information from each of these. An algorithm was also developed that captures the temperature and humidity data and sends it through the serial port to the LabView software, in which the visualization on the front panel and programming in the block diagram have been developed, being viewed from the HMI (Human Machine Interface). For the experimental tests, 3,309 grams of fermented cocoa beans were taken, and dried for 36 hours, removing a total mass of water of 1,650 grams. The results show an energy efficiency of 10.62%, concluding that the drying oven that takes advantage of the residual heat of an 18000 BTU condenser integrated with the proposed variable system is suitable for drying cocoa beans. Despite this efficiency being low, it meets the objective of removing moisture from them
A parabolic solar collector for harnessing solar energy in Bucaramanga, Colombia
In this work, a solar energy collection system based on a parabolic solar collector adjusted to the conditions and availability of energy was designed to examine this type of collection device and evaluate the energy potential when installed in an educational institution. To do this, data from the historical series of solar radiation compiled by the POWER project (Prediction of Worldwide Energy Resources) were analyzed and compared with data from the Institute of Hydrology, Meteorology and Environmental Studies in Colombia (IDEAM)
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events
Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402
Agricultural Waste Management Through Energy Producing Biorefineries: The Colombian Case
The effect of organic calcium channel modulators on the germination ofVaucheria longicaulis aplanospores
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
BACKGROUND
Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin,
a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2
diabetes and cardiovascular disease.
METHODS
In this randomized, double-blind study, we assigned 14,671 patients to add either
sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic
therapy was encouraged as required, aimed at reaching individually appropriate
glycemic targets in all patients. To determine whether sitagliptin was noninferior
to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The
primary cardiovascular outcome was a composite of cardiovascular death, nonfatal
myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.
RESULTS
During a median follow-up of 3.0 years, there was a small difference in glycated
hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo,
120.29 percentage points; 95% confidence interval [CI], 120.32 to 120.27). Overall,
the primary outcome occurred in 839 patients in the sitagliptin group (11.4%;
4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per
100 person-years). Sitagliptin was noninferior to placebo for the primary composite
cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001).
Rates of hospitalization for heart failure did not differ between the two groups
(hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant
between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic
cancer (P=0.32).
CONCLUSIONS
Among patients with type 2 diabetes and established cardiovascular disease, adding
sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular
events, hospitalization for heart failure, or other adverse events.
(Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes. Methods: ODYSSEY OUTCOMES was a randomised, double-blind, placebo-controlled trial, done at 1315 sites in 57 countries, that compared alirocumab with placebo in patients who had been admitted to hospital with an acute coronary syndrome (myocardial infarction or unstable angina) 1–12 months before randomisation and who had raised concentrations of atherogenic lipoproteins despite use of high-intensity statins. Patients were randomly assigned (1:1) to receive alirocumab or placebo every 2 weeks; randomisation was stratified by country and was done centrally with an interactive voice-response or web-response system. Alirocumab was titrated to target LDL cholesterol concentrations of 0·65–1·30 mmol/L. In this prespecified analysis, we investigated the effect of alirocumab on cardiovascular events by glycaemic status at baseline (diabetes, prediabetes, or normoglycaemia)—defined on the basis of patient history, review of medical records, or baseline HbA1c or fasting serum glucose—and risk of new-onset diabetes among those without diabetes at baseline. The primary endpoint was a composite of death from coronary heart disease, non-fatal myocardial infarction, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospital admission. ODYSSEY OUTCOMES is registered with ClinicalTrials.gov, number NCT01663402. Findings: At study baseline, 5444 patients (28·8%) had diabetes, 8246 (43·6%) had prediabetes, and 5234 (27·7%) had normoglycaemia. There were no significant differences across glycaemic categories in median LDL cholesterol at baseline (2·20–2·28 mmol/L), after 4 months' treatment with alirocumab (0·80 mmol/L), or after 4 months' treatment with placebo (2·25–2·28 mmol/L). In the placebo group, the incidence of the primary endpoint over a median of 2·8 years was greater in patients with diabetes (16·4%) than in those with prediabetes (9·2%) or normoglycaemia (8·5%); hazard ratio (HR) for diabetes versus normoglycaemia 2·09 (95% CI 1·78–2·46, p<0·0001) and for diabetes versus prediabetes 1·90 (1·65–2·17, p<0·0001). Alirocumab resulted in similar relative reductions in the incidence of the primary endpoint in each glycaemic category, but a greater absolute reduction in the incidence of the primary endpoint in patients with diabetes (2·3%, 95% CI 0·4 to 4·2) than in those with prediabetes (1·2%, 0·0 to 2·4) or normoglycaemia (1·2%, −0·3 to 2·7; absolute risk reduction pinteraction=0·0019). Among patients without diabetes at baseline, 676 (10·1%) developed diabetes in the placebo group, compared with 648 (9·6%) in the alirocumab group; alirocumab did not increase the risk of new-onset diabetes (HR 1·00, 95% CI 0·89–1·11). HRs were 0·97 (95% CI 0·87–1·09) for patients with prediabetes and 1·30 (95% CI 0·93–1·81) for those with normoglycaemia (pinteraction=0·11). Interpretation: After a recent acute coronary syndrome, alirocumab treatment targeting an LDL cholesterol concentration of 0·65–1·30 mmol/L produced about twice the absolute reduction in cardiovascular events among patients with diabetes as in those without diabetes. Alirocumab treatment did not increase the risk of new-onset diabetes. Funding: Sanofi and Regeneron Pharmaceuticals